Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife has decided to establish a Scientific Advisory Board to expand and assist in identifying future opportunities and offer invaluable insights into Qlife's research and development strategy. First to join Qlife Scientific Advisory Board is Dr. Jan Gorm Lisby, specialist in Molecular Diagnostics at the Department of Clinical Microbiology at Hvidovre Hospital, University of Copenhagen.
By meeting regularly Qlife's new Scientific Advisory Board will offer insights into the latest development within the specific fields of Molecular Diagnostics. The engagement of the members of the Board will provide invaluable input and assist in the targeted assay development, thereby accelerating the pace of innovation.
"Forming a Scientific Advisory Board is a strategic move for Qlife. By involving and interacting with highly experienced board members we will be able to add expert knowledge directly into our different programs", says Thomas Warthoe, CEO of Qlife.
First to join Qlife Scientific Advisory Board is Dr. Jan Gorm Lisby, a renowned and experienced specialist in Molecular Diagnostics, at Hvidovre Hospital, University of Copenhagen since 2005. Dr. Gorm Lisby has more than 20 years' experience in assay development, diagnostics, and treatment of severe infections, and is also founder of Anapa Biotech A/S, a molecular research tools company. He will be an advisor to Qlife's SARS-CoV2/influenza program/molecular program.
"Qlife has a well-positioned portfolio of projects and I look forward to assist in identifying new future opportunities concerning molecular research and assays", says Dr. Jan Gorm Lisby.
Eventually, Qlife intends to expand the Scientific Advisory Board with more members in targeted fields of expertise valuable to the company.
About Dr Jan Gorm Lisby
Dr. Jan Gorm Lisby gained his medical degree from the University of Copenhagen in 1987, and this was followed by a Post Doc position at the National Cancer Institute in Bethesda, Maryland, USA. In 1995 he gained his PhD in Molecular Microbiology from the University of Copenhagen. In 2000, he became board-certified specialist in Clinical Microbiology. Since 2005, Dr. Lisby has acted as senior physician at the Department of Clinical Microbiology, Hvidovre Hospital, University of Copenhagen, and has more than 20 years' experience in assay development, diagnostics, and treatment of severe infections.